RPHM - Reneo Pharmaceuticals, Inc. Stock Price and Quote

RPHM [NASD]

Index	-	P/E	-	EPS (ttm)	-2.00	Insider Own	1.20%	Shs Outstand	24.50M	Perf Week	2.33%
Market Cap	128.93M	Forward P/E	-	EPS next Y	-2.23	Insider Trans	0.00%	Shs Float	23.73M	Perf Month	73.25%
Income	-49.00M	PEG	-	EPS next Q	-0.59	Inst Own	75.40%	Short Float / Ratio	0.49% / 1.96	Perf Quarter	169.64%
Sales	-	P/S	-	EPS this Y	-102.30%	Inst Trans	0.46%	Short Interest	0.12M	Perf Half Y	89.37%
Book/sh	4.57	P/B	1.25	EPS next Y	-3.20%	ROA	-35.30%	Target Price	25.25	Perf Year	76.47%
Cash/sh	5.13	P/C	1.11	EPS next 5Y	-	ROE	-37.80%	52W Range	1.79 - 6.71	Perf YTD	144.64%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-15.05%	Beta	-
Dividend %	-	Quick Ratio	12.80	Sales past 5Y	-	Gross Margin	-	52W Low	218.44%	ATR	0.52
Employees	32	Current Ratio	12.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	61.22	Volatility	9.60% 12.86%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-1.70%	Profit Margin	-	Rel Volume	0.61	Prev Close	5.58
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	58.91K	Price	5.70
Recom	1.30	SMA20	12.02%	SMA50	52.35%	SMA200	84.08%	Volume	36,148	Change	2.15%

Sep-19-22

Resumed

H.C. Wainwright

Buy

$31

Jan-27-22

Initiated

Robert W. Baird

Outperform

$28

Dec-21-21

Initiated

H.C. Wainwright

Buy

$28

Nov-22-21

Initiated

Ladenburg Thalmann

Buy

$45

May-04-21

Initiated

SVB Leerink

Outperform

$25

May-04-21

Initiated

Piper Sandler

Overweight

$45

May-04-21

Initiated

Jefferies

Buy

$24

Mar-27-23 07:30AM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update GlobeNewswire
Mar-14-23 07:30AM	Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies GlobeNewswire
Mar-09-23 08:00AM	Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023 GlobeNewswire
Mar-03-23 06:07AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) largest shareholders are private equity firms who were rewarded as market cap surged US$33m last week Simply Wall St.
Feb-02-23 07:35AM	Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference GlobeNewswire
07:35AM	Loading…
Jan-31-23 07:35AM	Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD) GlobeNewswire
Dec-04-22 07:12AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Nov-08-22 07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results GlobeNewswire
Nov-03-22 08:00AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences GlobeNewswire
Sep-14-22 06:02AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) biggest owners are private equity firms who got richer after stock soared 25% last week Simply Wall St. +8.24%
Sep-06-22 08:35AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences GlobeNewswire
Aug-29-22 07:35AM	Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting GlobeNewswire
Aug-09-22 08:00AM	Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results GlobeNewswire -5.26%
Aug-04-22 09:10AM	Insiders who bought in the last 12 months lose an additional US$83k as Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) drops to US$57m Simply Wall St. +14.89%
Aug-02-22 07:30AM	Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors GlobeNewswire -15.92%
09:52AM	Loading…
Jul-26-22 09:52AM	Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development Benzinga
07:30AM	Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates GlobeNewswire
Jul-11-22 08:00AM	Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -6.84%
Jun-30-22 08:00AM	Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) GlobeNewswire +13.73%
Jun-20-22 08:33AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Invest In Growth? Simply Wall St.
May-10-22 04:05PM	Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results GlobeNewswire +9.09%
Mar-23-22 04:05PM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update GlobeNewswire
Mar-07-22 08:30AM	Reneo Pharmaceuticals Announces Senior Leadership Promotions GlobeNewswire
Feb-02-22 08:00AM	Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference GlobeNewswire -8.93%
Jan-24-22 08:00AM	Reneo Pharmaceuticals Announces Changes to its Board of Directors GlobeNewswire
Jan-10-22 11:55AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate Simply Wall St.
Dec-22-21 11:04AM	3 Strong Buy Stocks Under $10 With Triple-Digit Upside Potential TipRanks +15.28%
Nov-11-21 04:05PM	Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results GlobeNewswire +9.08%
Nov-01-21 04:05PM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences GlobeNewswire +6.71%
Oct-14-21 08:00AM	Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001 GlobeNewswire
02:35PM	Loading…
Oct-11-21 02:35PM	Here's What Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) Shareholder Ownership Structure Looks Like Simply Wall St.
08:00AM	Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer GlobeNewswire
Sep-28-21 08:26AM	Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies GlobeNewswire
Sep-09-21 09:12AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire -5.69%
Aug-11-21 05:55AM	Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results GlobeNewswire
Jul-28-21 08:00AM	Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study GlobeNewswire
Jul-12-21 09:30AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate Simply Wall St. +5.29%
Jul-09-21 08:00AM	Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction GlobeNewswire
Jul-07-21 08:00AM	Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference GlobeNewswire
Jun-29-21 08:00AM	Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices GlobeNewswire
May-20-21 06:00AM	Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results GlobeNewswire +6.34%
May-19-21 06:00AM	Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire +5.62%
Apr-13-21 08:14AM	The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga
Apr-09-21 12:32PM	Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today InvestorPlace
Apr-08-21 09:42PM	Reneo Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. The company was incorporated in 2014 and is headquartered in Irvine, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cruse Michael	Chief Operating Officer	Sep 01	Buy	3.39	7,500	25,448	13,697	Sep 02 05:12 PM
GREY MICHAEL G	Executive Chairman	Aug 31	Option Exercise	1.97	50,000	98,500	50,000	Sep 02 05:10 PM
Cruse Michael	Chief Operating Officer	Aug 31	Buy	3.21	3,212	10,307	6,197	Aug 31 05:47 PM
Cruse Michael	Chief Operating Officer	Aug 30	Buy	3.19	1,845	5,893	2,985	Aug 31 05:47 PM
Cruse Michael	Chief Operating Officer	Aug 30	Buy	3.16	975	3,081	31,758	Aug 31 05:47 PM
Cruse Michael	Chief Operating Officer	Aug 29	Buy	3.24	1,140	3,694	1,140	Aug 31 05:47 PM
Cruse Michael	Chief Operating Officer	Aug 29	Buy	3.24	83	269	30,783	Aug 31 05:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience